Silexion Therapeutics Corp (SLXN)
Nasdaq: SLXN · Biological Products, (No Diagnostic Substances) · Ramat Gan, IL · filing with the SEC since 2024
Who runs Silexion Therapeutics Corp
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Hadar Ilan
Chairman and CEO. First filing Aug 2024, latest Jun 8, 2026, 0 filings in all.
Officers reporting now
3
of 9 people with a filing in the last fifteen months
Directors reporting now
6
10 people on the record since 2024
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Hadar Ilan | Chairman and CEO | Aug 2024 | Jun 8, 2026 | none |
| Horenshtein Hadar Mirit | CFO and Secretary | Aug 2024 | Jun 8, 2026 | none |
| Shirvan Mitchell | CSO and CDO | Aug 2024 | Jun 8, 2026 | 1 · $0.00 |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Noy Shlomo | director | Aug 2024 | Feb 25, 2026 | none |
| Abramov Dror Yosef | director | Aug 2024 | Feb 23, 2026 | none |
| Alon Ruth | director | Aug 2024 | Feb 23, 2026 | none |
| Lushi Avner | director | Aug 2024 | Feb 23, 2026 | none |
| Peled Amnon | director | Dec 2024 | Feb 23, 2026 | none |
| Levin Ilan | director | Aug 2024 | Jan 27, 2026 | none |
Owners of more than 10% of a classsales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Moringa Sponsor, LP | 10% owner | Aug 2024 | Jan 27, 2026 | none |
Earlier names on the record4, newest filing first
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.